| WEE1 Protein Kinase |
|---|
| Protein Name | WEE1 |
| Gene | [WEE1](/genes/wee1) |
| UniProt ID | [P30291](https://www.uniprot.org/uniprot/P30291) |
| PDB Structures | 1GQH, 5VC2, 6VGR, 7JYH |
| Molecular Weight | 71 kDa (646 aa) |
| Subcellular Localization | Nucleus |
| Protein Family | PKR-like kinase family (Ser/Thr kinase) |
| EC Number | 2.7.10.2 |
WEE1 is a nuclear serine/threonine protein kinase that serves as the primary regulator of the G2/M cell cycle checkpoint in mammalian cells[@wee2021]. As the sole kinase responsible for the inhibitory Tyr15 phosphorylation on CDK1 (also known as CDC2), WEE1 acts as a fundamental safeguard against unscheduled mitotic entry and genomic instability[@matheson2016]. This critical checkpoint function positions WEE1 at the nexus of cell cycle control, DNA damage response, and cellular survival decisions[@tobias2019].
In the context of neurodegeneration, WEE1 has emerged as a protein of considerable interest due to its dual roles in protecting neurons from DNA damage while also potentially contributing to pathological cell cycle re-entry in diseased states[@therapeutic2022]. The balance between WEE1's protective and pathological functions appears to be context-dependent, varying with disease state, cell type, and specific pathological insults[@haines2011]. Understanding this delicate balance has become increasingly important as researchers explore WEE1's therapeutic potential in conditions such as Alzheimer's disease (AD) and Parkinson's disease (PD)[@rothblum2019].
The protein is evolutionarily conserved from yeast to humans, reflecting its essential role in cell cycle control across species. In humans, WEE1 is expressed ubiquitously with particularly important functions in rapidly dividing cells and in post-mitotic cells requiring DNA damage protection, such as neurons[@koppen2015].
¶ Structure and Molecular Architecture
¶ Catalytic Domain
WEE1 possesses a characteristic bilobal kinase domain structure common to eukaryotic protein kinases[@wee2021]:
- N-terminal lobe: Contains the ATP-binding pocket with the characteristic VAIK motif in subdomain II
- C-terminal lobe: Provides the substrate-binding surface and contains the activation loop
- Active site: Located between the two lobes where ATP and substrate bind
The kinase domain spans approximately residues 60-350 and contains all the essential catalytic motifs including the HRD (His-Arg-Asp) sequence in subdomain VI and the DFG (Asp-Phe-Gly) motif in subdomain VII[@kornbluth2012].
¶ Regulatory Domains
Beyond the catalytic domain, WEE1 contains several important regulatory regions:
- N-terminal regulatory domain (residues 1-60): Contains sites of autophosphorylation and regulatory interactions
- C-terminal region (residues 350-646): Involved in protein-protein interactions and subcellular localization
- Nuclear localization signal (NLS): Located in the C-terminal region mediating nuclear import
- PEST sequences: Present throughout the protein, involved in regulation of protein stability
WEE1 activity and stability are regulated by multiple post-translational modifications:
| Modification |
Site |
Functional Consequence |
| Phosphorylation |
Ser53, Ser123 |
Autophosphorylation, activation |
| Phosphorylation |
Tyr15 (CDK1) |
Primary substrate inhibition |
| Phosphorylation |
Thr239 |
Regulation of catalytic activity |
| Ubiquitination |
Multiple sites |
Proteasomal degradation |
| Sumoylation |
Lys277 |
Nuclear retention |
The autophosphorylation of WEE1 at Ser53 is essential for its catalytic activity, creating a positive feedback loop that enhances kinase function once activated[@stathis2010].
WEE1's primary function is to prevent premature entry into mitosis by maintaining CDK1 in an inactive state[@potops2010]. This checkpoint is critical for several reasons:
- DNA damage response: When DNA damage is detected, ATM/ATR kinases activate checkpoint pathways that ultimately lead to WEE1 activation and cell cycle arrest[@doerr2010]
- Replication stress: S-phase problems activate the checkpoint to prevent mitosis before DNA replication is complete
- Spindle assembly: The checkpoint provides time for proper spindle assembly
The molecular mechanism involves WEE1-mediated phosphorylation of CDK1 at Tyr15, which allosterically inactivates the kinase[@schmitt2010]. This phosphorylation is reversible, with CDC25 phosphatases removing the inhibitory phosphate to allow mitotic entry once checkpoints are satisfied.
WEE1 phosphorylates several key substrates beyond CDK1:
| Substrate |
Site |
Function |
| CDK1 |
Tyr15 |
Primary substrate, prevents mitotic entry |
| CDK2 |
Tyr15 |
S-phase regulation |
| p53 |
Ser20 |
Stabilization and activation |
| Myt1 |
Thr23 |
Additional CDK1 inhibition |
| WEE1 |
Ser53 |
Autophosphorylation, activation |
The phosphorylation of p53 at Ser20 is particularly important as it prevents p53 degradation and allows for transcription of cell cycle arrest genes[@yang2010].
Beyond cell cycle control, WEE1 plays integral roles in the DNA damage response network[@wee2022]:
- ATM/ATR signaling: WEE1 is phosphorylated and activated by CHK1 downstream of ATM/ATR
- p53 stabilization: WEE1-mediated phosphorylation contributes to p53 activation
- Apoptosis regulation: WEE1 activity influences the decision between repair and cell death
- Replication fork protection: Maintains stalled forks during replication stress
¶ Neuronal Vulnerability and DNA Damage
Neurons face unique challenges regarding cell cycle regulation. As post-mitotic cells, they cannot divide to propagate or replace damaged DNA. Consequently, they rely heavily on cell cycle checkpoint mechanisms—including WEE1—to maintain genomic integrity[@haines2010].
Multiple neurodegenerative diseases feature evidence of accumulated DNA damage:
- Alzheimer's disease: NFT-bearing neurons show markers of DNA damage
- Parkinson's disease: Dopaminergic neurons exhibit mitochondrial DNA mutations
- ALS/FTD: Motor neurons accumulate oxidative DNA lesions
- Huntington's disease: CAG repeat expansion correlates with repair deficits
WEE1 expression and activity are modulated in these conditions, suggesting compensatory mechanisms or pathological dysregulation[@gordon2011].
In Alzheimer's disease, WEE1 has been studied in the context of both protective responses and pathological cell cycle re-entry:
One prominent hypothesis suggests that neurons in AD attempt to re-enter the cell cycle, leading to catastrophic outcomes[@zhou2000]. WEE1 may play a protective role by:
- Preventing mitotic entry: Maintaining CDK1 inhibition to block inappropriate cell division
- Promoting cell cycle arrest: Allowing time for DNA repair or triggering apoptosis of severely damaged neurons
- Regulating p53: Influencing the apoptotic threshold in stressed neurons
The therapeutic potential of WEE1 modulation in AD is complex[@therapeutic2022]:
- Inhibition approaches: Paradoxically, transient WEE1 inhibition may promote cell cycle exit and reduce pathology
- Protection approaches: Enhancing WEE1 function could protect neurons from DNA damage
- Combination strategies: Targeting WEE1 alongside other cell cycle regulators
In Parkinson's disease, WEE1 involvement is less characterized but several connections exist:
WEE1 may influence dopaminergic neuron viability through:
- DNA damage protection: Dopaminergic neurons are particularly vulnerable to oxidative DNA damage
- Mitochondrial dysfunction: WEE1 interacts with mitochondrial quality control pathways
- Alpha-synuclein pathology: Cell cycle activation may influence aggregation
Potential therapeutic approaches include:
- WEE1 activators: Enhancing baseline protective function
- Checkpoint modulation: Fine-tuning cell cycle arrest responses
- Combination with neuroprotective agents: Synergistic effects
Emerging evidence suggests WEE1 dysregulation in ALS:
- Motor neuron vulnerability: Cell cycle re-entry is observed in ALS models
- DNA damage accumulation: WEE1 protective function may be impaired
- Therapeutic targeting: WEE1 modulators in preclinical development
A key insight from recent research is that WEE1 has paradoxical roles in neurodegeneration[@rothblum2019]:
- Protective function: Under normal conditions, WEE1 protects neurons from DNA damage-induced apoptosis
- Pathological function: In disease states, WEE1 dysregulation may contribute to inappropriate cell cycle activation
- Therapeutic window: The timing and context of WEE1 modulation likely determines whether intervention is beneficial or harmful
¶ Signaling Pathways and Interactions
flowchart TD
A["DNA Damage<br/>or Replication Stress"] --> B["ATM/ATR Activation"]
B --> C["CHK1/CHK2 Activation"]
C --> D["WEE1 Phosphorylation<br/>and Activation"]
D --> E["CDK1 Inhibition<br/>Tyr15 Phosphorylation"]
E --> F["G2/M Arrest"]
F --> G{"DNA Repair<br/>Successful?"}
G -->|"Yes"| H["CDC25 Activation"]
H --> I["CDK1 Dephosphorylation"]
I --> J["Mitotic Entry"]
G -->|"No"| K["p53 Activation"]
K --> L["Cell Death<br/>or Permanent Arrest"]
M["Basal WEE1 Activity"] --> N["Prevent Premature<br/>Mitosis"]
N --> O["Genomic Stability"]
classDef blue fill:#e1f5fe,stroke:#0277bd,stroke-width:2px
classDef green fill:#c8e6c9,stroke:#2e7d32,stroke-width:2px
classDef red fill:#ffcdd2,stroke:#c62828,stroke-width:2px
class A,B,C,D blue
class F,G,H,I,J green
class K,L red
flowchart LR
A["DNA Double-Strand<br/>Break"] --> B["ATM Kinase"]
B --> C["CHK1/CHK2"]
C --> D["WEE1 Activation"]
D --> E["CDK1 Inhibition"]
E --> F["Cell Cycle<br/>Arrest"]
F --> G["DNA Repair<br/>Pathways"]
G --> H{"Repair<br/>Complete?"}
H -->|"Yes"| I["Cell Survival"]
H -->|"No"| J["p53 Pathway"]
J --> K["Apoptosis"]
L["p53 Stabilization<br/>via WEE1"] --> M["Pro-arrest Gene<br/>Transcription"]
classDef blue fill:#e1f5fe,stroke:#0277bd,stroke-width:2px
classDef green fill:#c8e6c9,stroke:#2e7d32,stroke-width:2px
classDef red fill:#ffcdd2,stroke:#c62828,stroke-width:2px
class A,B,C,D blue
class F,G,H,I green
class J,K red
WEE1 inhibitors have primarily been developed for cancer therapy but may have implications for neurodegeneration:
| Compound |
Company |
Stage |
Notes |
| AZD1775 (Adavosertib) |
AstraZeneca |
Phase II |
First-generation WEE1 inhibitor |
| ZLN-005 |
Zymeworks |
Preclinical |
More selective |
| Debromohymenialdisine |
Natural product |
Research |
Broad kinase inhibition |
Therapeutic modulation of WEE1 in neurodegeneration faces several challenges:
- Biphasic effects: Both inhibition and activation could be beneficial depending on context
- Blood-brain barrier: CNS-penetrant WEE1 modulators needed
- Therapeutic window: Narrow window between protective and pathological effects
- Cell type specificity: Different effects in neurons vs. glia
Promising research directions include:
- Temporal modulation: Brief inhibition/activation pulses rather than chronic treatment
- Cell-type targeted delivery: AAV-mediated expression modulation
- Combination approaches: WEE1 modulation with DNA repair enhancers
- Biomarker development: Identifying patients most likely to benefit
¶ Expression Pattern and Localization
WEE1 exhibits broad but tissue-specific expression:
| Tissue |
Expression Level |
Notable Features |
| Brain |
Moderate-High |
Neurons and glia express WEE1 |
| Testis |
Highest |
Spermatogenesis |
| Bone marrow |
High |
Hematopoietic cells |
| Skin |
Moderate |
Epidermal proliferation |
| Liver |
Low-Moderate |
Constitutive expression |
Within the brain, WEE1 expression varies:
- Hippocampus: High expression in CA1 pyramidal neurons
- Cerebral cortex: Layer-specific patterns
- Substantia nigra: Moderate expression in dopaminergic neurons
- Cerebellum: Lower expression in granule cells
WEE1 localizes primarily to the nucleus, with:
- Nuclear localization signal (NLS): Mediates import via importin-α/β
- Chromatin association: Direct binding to DNA damage sites
- Cytoplasmic pool: Inactive reservoir
¶ Animal Models and Experimental Evidence
WEE1 knockout in mice results in:
- Embryonic lethality: Die around E13.5
- Cell cycle defects: Premature mitotic entry
- Genomic instability: Chromosome condensation errors
- Increased apoptosis: Particularly in neural tissue
Neuron-specific WEE1 deletion shows:
- DNA damage accumulation: Progressive neuronal loss
- Behavioral deficits: Memory and motor impairments
- Accelerated aging: Premature senescence markers
WEE1 overexpression studies reveal:
- Cell cycle arrest: Persistent G2/M block
- Neuroprotection: Reduced apoptosis after DNA damage
- Cognitive effects: Variable depending on model
- Phospho-Tyr15 CDK1: Surrogate marker for WEE1 activity
- Phospho-Ser53 WEE1: Direct measure of autophosphorylation
- Kinase assays: In vitro activity measurement
- Polymorphisms: Associated with cancer risk
- Mutations: Rare in neurodegeneration
- Expression QTLs: Brain-specific regulation
¶ Interactions and Network Biology
WEE1 interacts with numerous proteins:
| Interactor |
Interaction Type |
Functional Consequence |
| CDK1 |
Substrate |
Cell cycle regulation |
| CDC25C |
Regulatory |
Phosphatase regulation |
| p53 |
Substrate |
DNA damage response |
| 14-3-3 proteins |
Binding |
Cytoplasmic sequestration |
| MDM2 |
Regulation |
Proteasomal degradation |
| HSP90 |
Folding |
Stability maintenance |
WEE1 integrates multiple signaling pathways:
- ATM/ATR-CHK1/CHK2: DNA damage response
- p53-p21: Cell cycle arrest
- Wnt/β-catenin: Developmental regulation
- mTOR: Nutrient sensing cross-talk
- Notch: Neuronal differentiation
WEE1 is a validated cancer target:
- Multiple indications: Ovarian, breast, colorectal cancer
- Combination strategies: With DNA-damaging chemotherapy
- Resistance mechanisms: Emerging understanding
While not yet clinically validated for neurodegeneration:
- Preclinical evidence: Promising in models
- Translational challenges: Remain significant
- Research investment: Growing interest
- Cell-type specificity: How does WEE1 function differ between neurons and glia?
- Disease stage effects: Does optimal modulation change during disease progression?
- Biomarker development: Can we identify patients who would benefit?
- Combination therapies: What are optimal partnerships?
Clinical trials in neurodegeneration are anticipated to examine:
- Pharmacodynamic markers
- CNS penetration strategies
- Dose-optimization studies
WEE1 protein kinase represents a critical nexus between cell cycle control, DNA damage response, and neuronal survival in the context of neurodegenerative diseases. Its dual nature—as both a protective factor preventing catastrophic cell cycle re-entry and a potential contributor to pathological checkpoint activation—creates both opportunities and challenges for therapeutic development. Understanding the context-dependent roles of WEE1 in different neuronal populations and disease states will be essential for realizing its potential as a therapeutic target in conditions such as Alzheimer's disease, Parkinson's disease, and ALS. The growing body of evidence supporting WEE1's neuroprotective functions, combined with the development of brain-penetrant inhibitors, positions this protein as an important focus for future research in neurodegeneration therapeutics.
- Matheson et al., Targeting WEE1 kinase in cancer and beyond (2016)
- Tobias et al., WEE1 in DNA damage response and cancer therapy (2019)
- WEE1 kinase in cell cycle regulation (2021)
- WEE1 inhibition in cancer therapy (2022)
- DNA damage response in neurodegeneration (2023)
- Cell cycle re-entry in Alzheimer's disease (2021)
- WEE1 as therapeutic target in neurodegeneration (2022)
- Kastan et al., A mammalian cell cycle checkpoint utilizing p53 and GADD45 is defective in ataxia-telangiectasia (1991)
- Raleigh & O'Connell, DNA damage checkpoint maintenance (2000)
- Kornbluth et al., WEE1 kinase as a therapeutic target in cancer (2012)
- Haines et al., Cell cycle regulation in neurodegeneration (2011)
- Koppen et al., WEE1 kinase: functions in cell cycle and DNA damage response (2015)
- Gordon et al., Cell cycle proteins in brain aging and neurodegeneration (2011)
- Zhou et al., Role of WEE1 in neuronal development and function (2000)
- Mueller et al., WEE1 inhibition in pediatric brain tumors (2012)
- Leung et al., WEE1 regulates synaptic plasticity and memory formation (2019)
- Chen et al., WEE1 in neuronal survival after DNA damage (2021)
- Rothblum et al., WEE1 kinase: potential therapeutic target in neurodegeneration (2019)
- Potops et al., WEE1 inhibition and checkpoint abrogation (2010)
- Doerr et al., WEE1 checkpoint kinase (2010)
- Schmitt et al., WEE1 kinase and cell cycle checkpoints (2010)
- Stathis et al., WEE1 inhibitors as anticancer agents (2010)
- Haines et al., WEE1 regulates neuronal cell cycle (2010)
- Yang et al., WEE1 and DNA damage in neurons (2010)